Compare · MDLN vs TFX
MDLN vs TFX
Side-by-side comparison of Medline Inc. (MDLN) and Teleflex Incorporated (TFX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and TFX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.15B, about 7.7x TFX ($5.75B).
- Over the past year, MDLN is down 17.5% and TFX is up 5.7% - TFX leads by 23.2 points.
- MDLN has been more active in the news (21 items in the past 4 weeks vs 16 for TFX).
- Both have 25 recent analyst ratings on file.
- Company
- Medline Inc.
- Teleflex Incorporated
- Price
- $33.60-2.50%
- $129.66-1.75%
- Market cap
- $44.15B
- $5.75B
- 1M return
- -19.90%
- +5.14%
- 1Y return
- -17.55%
- +5.68%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 21
- 16
- Recent ratings
- 25
- 25
Teleflex Incorporated
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)
Latest TFX
- Teleflex Incorporated Announces Pricing of $500 Million Senior Notes Offering
- Teleflex Incorporated filed SEC Form 8-K: Other Events, Regulation FD Disclosure
- Teleflex Incorporated Announces Private Offering of $500 Million of Senior Notes Due 2032
- SEC Form SD filed by Teleflex Incorporated
- Teleflex Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Teleflex Showcases New Clinical Data at Leading Urological Congresses Highlighting Patient Experience Advantages of the UroLift™ System and Long-Term Toxicity Reduction with Barrigel™ Rectal Spacer
- Teleflex Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Ryu Jaewon was granted 1,090 shares, increasing direct ownership by 29% to 4,817 units (SEC Form 4)
- Director Krakauer Andrew A was granted 1,090 shares, increasing direct ownership by 15% to 8,309 units (SEC Form 4)
- Director Haggerty Gretchen R was granted 1,090 shares, increasing direct ownership by 17% to 7,395 units (SEC Form 4)